Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS20052190HPVENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS20052449HPVENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS44027221HTLV-1ENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS44028187HTLV-1ENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS44051118HTLV-1ENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS44051119HTLV-1ENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS44051120HTLV-1ENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS44047334HTLV-1ENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS44051121HTLV-1ENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TVIS44034836HTLV-1ENSG00000137764.20protein_codingMAP2K5NoNo5607Q13163
TCGA Plot Options
Drug Information
GeneMAP2K5
DrugBank IDDB12010
Drug NameFostamatinib
Target IDBE0009460
UniProt IDQ13163
Regulation Typeinhibitor
PubMed IDs26516587
CitationsRolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4.
GroupsApproved; Investigational
Direct ClassificationMethoxyanilines
SMILESCOC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC
Pathways
PharmGKB
ChEMBLCHEMBL2103830